7Baggers

ImmunityBio, Inc
(NASDAQ:IBRX) 

IBRX stock logo

ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy. It develops an albumin-linked chemotherapeutic therapy (Aldoxorubicin), a novel IL-15 cytokine superagonist (N-803), checkpoint inhibitors, m...

Founded: 2014
Sector: Healthcare
Industry: Biotechnology
Healthcare
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
  • Commercial Launch Progress Hinges on ANKTIVA Uptake: ImmunityBio’s near-term outlook is driven by early commercialization execution for ANKTIVA (nogapendekin alfa inbakicept), including demand generation, payer coverage, and provider adoption in its initial indicated setting.
  • High Cash Burn Risk Until Revenue Scales: As a clinical-stage-to-commercial transition company, ImmunityBio typically faces elevated operating expenses (manufacturing, sales build-out, and R&D), meaning liquidity and runway depend on how quickly product revenue ramps versus ongoing spend.
  • Regulatory/Label Expansion Could Be a Major Catalyst: Potential upside is tied to additional regulatory progress and label expansion efforts across other oncology indications, which could broaden the addressable market and improve long-term revenue potential.
  • Manufacturing and Supply Execution Remains Critical: Biologics manufacturing scale-up and quality systems are key operational variables; any supply constraints or remediation requirements could impact near-term sales and margins.
  • Dilution and Financing Overhang Likely Persists: Given the capital intensity of commercialization and clinical development, investors often watch for potential equity issuance, debt financing, or partnership structures that could affect ownership dilution and balance sheet flexibility.
Bull Thesis:
  • FDA Approval of Anktiva for Bladder Cancer: The recent FDA approval of Anktiva (N-803) in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) provides ImmunityBio with its first commercial product and a clear path to significant revenue generation.
  • Substantial Market Opportunity in NMIBC: The approved indication addresses a large and underserved patient population in BCG-unresponsive NMIBC, where current treatment options are limited. This represents a multi-billion dollar market opportunity for Anktiva.
  • Robust Pipeline and Platform Potential: Beyond bladder cancer, Anktiva and other assets are being investigated in multiple other solid tumors (e.g., pancreatic cancer), leveraging the company's IL-15 superagonist and adenovirus-based platforms, suggesting future growth drivers.
  • Strong Leadership and Strategic Ecosystem: The company benefits from the leadership of Dr. Patrick Soon-Shiong and the broader NantWorks ecosystem, providing deep scientific expertise, strategic partnerships, and potential for synergistic development.
Bear Thesis:
  • Commercialization Challenges and Slow Ramp-up: Despite FDA approval, the successful commercialization of Anktiva faces hurdles including market access, physician adoption, reimbursement complexities, and competition, potentially leading to a slower revenue ramp-up than investor expectations.
  • Continued High Cash Burn and Potential Dilution: ImmunityBio has historically operated with significant cash burn. While Anktiva's approval offers revenue potential, the company may still require substantial capital to fund its commercial launch and ongoing pipeline, potentially leading to future equity dilution.
  • Intense Competition in Bladder Cancer Market: The market for bladder cancer treatments, particularly in the BCG-unresponsive setting, is competitive, with established players (e.g., Keytruda) and other novel therapies in development. ImmunityBio must effectively differentiate Anktiva to capture market share.
  • High Reliance on Single Product Success: ImmunityBio's immediate financial success and path to profitability are heavily reliant on Anktiva's commercial performance in BCG-unresponsive NMIBC. Any unforeseen issues with its launch or adoption could significantly impact near-term revenue.
Main Competitors:
  • Merck & Co., Inc. ($MRK) (Keytruda (pembrolizumab)), Merck's Keytruda is a leading PD-1 inhibitor approved for various cancers, including BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). It directly competes with ImmunityBio's newly approved Anktiva (N-803) + BCG combination in this specific indication, offering an alternative immunotherapy option for patients.
  • Ferring Pharmaceuticals (Adstiladrin (nadofaragene firadenovec-vncg)), Ferring's Adstiladrin is a gene therapy approved for BCG-unresponsive NMIBC. This product is a direct competitor to ImmunityBio's Anktiva + BCG combination, targeting the same patient population with a different mechanism of action (adenovirus-mediated interferon alfa-2b gene delivery).
  • Bristol Myers Squibb (BMS) ($BMY) (Opdivo (nivolumab), Yervoy (ipilimumab), broad oncology pipeline), BMS is a major player in oncology and immunotherapy with a broad portfolio, including PD-1 inhibitors like Opdivo. While not directly approved for BCG-unresponsive NMIBC CIS, BMS competes in the broader bladder cancer and solid tumor immunotherapy landscape, and has significant resources and pipeline depth in areas like cell therapies and novel immunotherapies that overlap with ImmunityBio's strategic focus.
  • Fate Therapeutics, Inc. ($FATE) (Allogeneic NK cell therapies (e.g., FT516, FT596)), ImmunityBio is developing its own NK cell therapies as part of its pipeline. Fate Therapeutics is a leader in the development of off-the-shelf, induced pluripotent stem cell (iPSC)-derived NK cell and T-cell immunotherapies for cancer, directly competing with ImmunityBio's efforts in the allogeneic NK cell therapy space for various hematologic and solid tumors.
Moat:
ImmunityBio operates in a highly competitive biotechnology landscape, particularly within oncology and immunotherapy. Its primary competitive advantage, or 'moat,' stems from its unique pipeline, especially the recently FDA-approved Anktiva (N-803), an IL-15 superagonist, which represents a novel mechanism of action for stimulating NK and T cells. This approval for BCG-unresponsive NMIBC CIS establishes a foothold in a niche but significant market. ImmunityBio also emphasizes a 'quintuple combination' approach, aiming to leverage multiple therapeutic modalities (NK cells, T cells, vaccines, oncolytic viruses, cytokines) to achieve deeper and more durable responses, which could differentiate its future pipeline. Furthermore, its integrated manufacturing capabilities could offer strategic advantages. However, the competitive landscape is formidable. ImmunityBio faces direct competition from established pharmaceutical giants like Merck (Keytruda) and emerging biotechs like Ferring (Adstiladrin) in its approved NMIBC indication. Broader competition comes from companies with extensive oncology pipelines and resources, such as Bristol Myers Squibb, and specialized firms like Fate Therapeutics in the rapidly evolving NK cell therapy space. These competitors often possess larger R&D budgets, established commercial infrastructures, and broader market access. ImmunityBio's ability to expand Anktiva's indications, successfully advance its other pipeline assets, and effectively commercialize its approved product will be critical in navigating this intense competitive environment.
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 
                                                
      revenue
    		        40,000 139,000 82,000 41,000 360,000 73,000 118,000 35,000 14,000 390,000 66,000 339,000 139,000 21,000 68,000 1,000 21,000 9,000 12,000 17,000 5,000 7,000 31,000 4,000 5,000 12,000 8,000 14,000 11,000 14,000 12,000 12,000 6,000 14,000 10,000 91,000 
      product revenue
    		44,167,000 38,272,000 31,780,000 26,421,000 16,509,000 7,206,000 5,954,000 990,000                                     
      other revenues
    		39,000 13,000 281,000 4,000 8,000 346,000 152,000 57,000                                     
      total revenue
    		44,206,000 38,285,000 32,061,000 26,425,000 16,517,000 7,552,000 6,106,000 1,047,000                                     
      yoy
    		167.64% 406.95% 425.07% 2423.88%                                         
      qoq
    		15.47% 19.41% 21.33% 59.99% 118.71% 23.68% 483.19%                                      
      operating costs and expenses
    		                                            
      cost of sales
    		238,000 382,000 177,000 136,000 58,000                                        
      research and development
    		64,770,000 60,808,000 48,661,000 52,430,000 45,976,000 35,221,000 50,443,000 51,129,000 53,351,000 51,532,000 48,402,000 53,168,000 79,264,000 58,077,000 71,612,000 63,082,000 55,378,000 51,753,000 49,277,000 53,800,000 41,128,000 20,256,000 17,284,000 13,709,000 13,234,000 12,004,000 12,052,000 13,131,000 12,598,000 12,480,000 14,559,000 14,688,000 13,991,000 12,021,000 11,069,000 9,706,000 9,248,000 9,445,000 8,364,000 6,389,000 4,944,000 5,106,000 3,950,000 1,745,000 
      research and development – related parties
    		3,219,000 3,049,000 2,571,000 2,806,000 2,258,000                                        
      selling, general and administrative
    		44,461,000 37,833,000 35,508,000 41,862,000 31,977,000 41,731,000 35,916,000 49,251,000 41,885,000 33,110,000 31,816,000 32,018,000 32,676,000 26,215,000 19,310,000 16,575,000 40,608,000 27,911,000 29,625,000 32,445,000 45,275,000 10,651,000 4,711,000 6,519,000 5,373,000 4,116,000 4,025,000 4,182,000 5,742,000 5,246,000 9,580,000 13,594,000 14,298,000 13,385,000 13,381,000 14,128,000 16,227,000 15,713,000 24,423,000 28,588,000 26,651,000 74,831,000 38,854,000 82,429,000 
      selling, general and administrative – related parties
    		1,309,000 896,000 774,000 476,000 677,000                                        
      total operating costs and expenses
    		113,997,000 102,968,000 87,691,000 97,710,000 80,946,000 76,952,000 86,359,000 100,380,000                                     
      income from operations
    		-69,791,000 -64,683,000 -55,630,000 -71,285,000 -64,429,000 -69,400,000 -80,253,000 -99,333,000 -95,196,000 -85,389,000 -80,136,000 -85,145,000 -111,580,000 -84,900,000 -90,804,000 -79,622,000 -95,972,000 -79,274,000 -78,836,000 -85,906,000 -86,264,000 -30,886,000 -21,927,000 -20,227,000 -18,586,000 -16,111,000 -16,065,000 -17,296,000 -18,335,000 -17,719,000 -24,108,000 -28,278,000 -28,284,000 -25,394,000 -24,442,000 -23,820,000 -25,464,000 -25,144,000 -32,775,000 -34,965,000 -31,589,000 -79,923,000 -42,794,000 -84,083,000 
      yoy
    		8.32% -6.80% -30.68% -28.24% -32.32% -18.72% 0.15% 16.66% -14.68% 0.58% -11.75% 6.94% 16.26% 7.10% 15.18% -7.31% 11.25% 156.67% 259.54% 324.71% 364.13% 91.71% 36.49% 16.95% 1.37% -9.08% -33.36% -38.84% -35.18% -30.22% -1.37% 18.72% 11.07% 0.99% -25.42% -31.87% -19.39% -68.54% -23.41% -58.42%     
      qoq
    		7.90% 16.27% -21.96% 10.64% -7.16% -13.52% -19.21% 4.35% 11.49% 6.56% -5.88% -23.69% 31.43% -6.50% 14.04% -17.04% 21.06% 0.56% -8.23% -0.42% 179.30% 40.86% 8.40% 8.83% 15.36% 0.29% -7.12% -5.67% 3.48% -26.50% -14.75% -0.02% 11.38% 3.89% 2.61% -6.46% 1.27% -23.28% -6.26% 10.69% -60.48% 86.76% -49.11%  
      operating margin %
    		-157.88% -168.95% -173.51% -269.76% -390.08% -918.96% -1314.33% -9487.39% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% 
      other income
    		 -126,500 -187,000   -6,250 12,000   -71,000 -1,047,000 -28,000  -923,000 6,000 185,000 -4,000 -59,000 -38,000 277,000 13,000 -1,272,000 96,000 67,000 32,000 112,000 56,000 83,000 47,000 -19,000 47,000 39,000 169,000 244,000 87,000 -283,000 109,000 -1,000 60,000 1,000 28,000 -87,000 61,000  
      interest and investment income
    		2,314,000 2,298,000 2,067,000 1,153,000 887,000 1,187,000 1,798,000 1,891,000 3,099,000 484,000 35,000 -61,000 673,000 -3,813,000 857,000 -1,800,000 1,666,000 -6,926,000 -5,941,000 -177,000 8,944,000                        
      change in fair value of warrant liabilities
    		-295,413,000 30,743,000 14,905,000 3,889,000 -448,000 9,733,000 31,324,000 -19,300,000 -1,802,000 -79,400,000 14,265,000 -10,019,000 27,554,000                                
      change in fair value of related-party convertible note
    		-236,625,000 -191,000 -1,169,000 1,169,000 -42,582,000                                        
      interest expense – related party
    		-14,559,000 -14,843,000 -15,256,000 -15,474,000 -15,313,000                                        
      interest expense related to revenue interest liability
    		-13,871,000 -12,299,000 -12,302,000 -13,405,000 -13,534,000 -11,503,000 -10,925,000 -9,225,000 -8,004,000                                    
      change in fair value of derivative liabilities
    		1,108,000 -1,400,000 289,000 1,931,000 5,578,000 -6,607,000 1,614,000 21,194,000 -2,724,000                                    
      interest expense
    		-34,000 -50,000 -26,000 -5,000 -18,000 -26,071,000 -29,322,000 -29,794,000 -29,483,000 -32,126,000 -35,021,000 -32,235,000 -29,816,000 -28,562,000 -16,764,000 -9,698,000 -8,491,000 -4,490,000 -3,614,000 -3,577,000 -3,168,000 -22,000 -9,000 -3,000 -7,000 -11,000 -5,000  -3,000 -145,000 -149,000 -106,000 -33,000 -34,000 -393,000 -154,000 -37,000 -37,000 -29,000      
      other expense
    		-5,917,000   -278,000 -41,000   -17,000 -20,000    -1,077,000                                
      total other expense
    		-562,997,000 2,590,000 -11,679,000 -21,020,000 -65,471,000 -19,921,000 -5,499,000 -35,251,000 -38,934,000 -148,065,000 -15,506,000 -53,068,000 -5,003,000     -12,278,000 -9,593,000                          
      loss before income taxes and noncontrolling interest
    		-632,788,000                                            
      income tax benefit
    		-9,000  35,000  234,000             -1,000    1,000 -2,000 -4,000  63,000  -2,000 36,000 128,000 128,000 123,000 -124,000 -172,000 -99,000 -124,000 -98,000        
      net income
    		-632,797,000 -61,958,000 -67,274,000 -92,574,000 -129,666,000 -59,179,000 -85,752,000 -134,584,000 -134,130,000 -233,414,000 -95,642,000 -138,213,000 -116,583,000 -108,326,000 -111,161,000 -94,835,000 -102,998,000 -91,553,000 -88,429,000 -89,385,000 -80,481,000 -32,132,000 -21,776,000 -20,092,000 -18,383,000 -15,641,000 -15,581,000 -16,682,000 -17,885,000 -17,340,000 -23,635,000 -27,732,000 -27,519,000 -24,487,000 -23,969,000 -23,452,000 -24,515,000 -24,238,000 -31,897,000 -33,997,000 -30,650,000 -76,821,000 -42,649,000 -84,581,000 
      yoy
    		388.02% 4.70% -21.55% -31.21% -3.33% -74.65% -10.34% -2.63% 15.05% 115.47% -13.96% 45.74% 13.19% 18.32% 25.71% 6.10% 27.98% 184.93% 306.08% 344.88% 337.80% 105.43% 39.76% 20.44% 2.78% -9.80% -34.08% -39.85% -35.01% -29.19% -1.39% 18.25% 12.25% 1.03% -24.86% -31.02% -20.02% -68.45% -25.21% -59.81%     
      qoq
    		921.33% -7.90% -27.33% -28.61% 119.11% -30.99% -36.28% 0.34% -42.54% 144.05% -30.80% 18.55% 7.62% -2.55% 17.22% -7.93% 12.50% 3.53% -1.07% 11.06% 150.47% 47.56% 8.38% 9.30% 17.53% 0.39% -6.60% -6.73% 3.14% -26.63% -14.77% 0.77% 12.38% 2.16% 2.20% -4.34% 1.14% -24.01% -6.18% 10.92% -60.10% 80.12% -49.58%  
      net income margin %
    		-1431.47% -161.83% -209.83% -350.33% -785.05% -783.62% -1404.39% -12854.25% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% 
      net loss attributable to noncontrolling interests, net of tax
    		-15,000 -14,000 -21,000 -19,000 -20,000 -17,000 -23,000 -20,000 -21,000 -22,000 -60,000 -334,000 -240,000    -172,000 -294,000 -800,000  -867,000                        
      net loss attributable to immunitybio common stockholders
    		-632,782,000 -61,944,000 -67,253,000 -92,555,000 -129,646,000 -59,162,000 -85,729,000 -134,564,000 -134,109,000 -233,392,000 -95,582,000 -137,879,000 -116,343,000    -102,826,000 -91,259,000 -87,629,000  -79,614,000                        
      net loss per immunitybio common share – basic and diluted
    		-620       -200 -200 -380 -190 -320 -270     -165 -220  -210                        
      weighted-average number of common shares used in computing net loss per share – basic and diluted
    		1,026,874       686,938,120 672,831,258 508,635,592 498,375,316 437,456,657 428,381,485 399,900,374   397,882,441 389,234,156 391,853,623  382,741,464                        
      loss before income taxes and noncontrolling interests
    		 -62,093,000 -67,309,000 -92,305,000 -129,900,000 -59,179,000 -85,752,000 -134,584,000 -134,130,000 -233,454,000 -95,642,000 -138,213,000 -116,583,000    -102,998,000 -91,552,000 -88,429,000  -80,475,000                        
      net loss per immunitybio common share – basic
    		 -60 -70 -100 -150 -70 -120          -260                            
      net loss per immunitybio common share – diluted
    		 -60 -70 -100 -150 -90 -140          -260                            
      weighted-average number of common shares used in computing net loss per share – basic
    		 919,863 946,601 888,216 853,162 697,312 695,895                                      
      weighted-average number of common shares used in computing net loss per share – diluted
    		 919,863 946,601 888,216 853,162 700,443 697,961                                      
      income tax expense
    		   -269,000                -2,000 -6,000                     250   
      cost of product revenue
    		                                            
      loss on equity method investment
    		          -1,255,000 -3,957,000 -2,337,000 -3,554,000 -4,456,000 -3,900,000 -197,000                            
      operating expenses:
    		                                            
      total operating expenses
    		        95,236,000 85,528,000 80,218,000 85,186,000 111,940,000 84,973,000 90,922,000 79,657,000 95,986,000 79,664,000 78,902,000 86,245,000 86,403,000 30,907,000 21,995,000 20,228,000 18,607,000 16,120,000 16,077,000 17,313,000 18,340,000 17,726,000 24,139,000 28,282,000 28,289,000 25,406,000 24,450,000 23,834,000 25,475,000 25,158,000 32,787,000 34,977,000 31,595,000 79,937,000 42,804,000 84,174,000 
      other expense, net:
    		                                            
      change in fair value of convertible note
    		         187,250 7,517,000 -6,768,000                                 
      other income, net:
    		                                            
      total other income
    		             -10,649,000 -20,357,000 -15,213,000 -7,026,000   -3,477,000 5,789,000 -1,247,000 153,000 139,000 203,000 407,000 484,000 616,000 414,000 251,000 345,000 423,000 641,000 735,000 374,000 244,000 851,000 757,000 826,000 740,000 796,000 -275,250 145,000  
      income before income taxes and noncontrolling interests
    		             -77,248,500 -111,161,000 -94,835,000    -89,383,000                         
      net income attributable to noncontrolling interests, net of tax
    		             -160,500 -223,000 -247,000    -1,097,000                         
      net income attributable to immunitybio common stockholders
    		             -77,088,000 -110,938,000 -94,588,000    -88,288,000                         
      net income per immunitybio common share – basic and diluted
    		             -192.5 -280 -240    -230                         
      weighted-average number of common shares used in computing net income per share – basic and diluted
    		              400,059,707 397,991,630    384,820,486                         
      impairment of intangible assets
    		                                            
      other income:
    		                                            
      investment income
    		                     47,000 66,000 75,000 178,000 306,000 433,000 533,000 370,000 415,000 447,000 490,000 505,000 525,000 680,000 681,000 779,000 795,000 795,000 739,000 768,000    
      income before income taxes
    		                     -32,133,000 -21,774,000 -20,088,000 -18,383,000 -15,704,000 -15,581,000 -16,680,000 -17,921,000 -17,468,000 -23,763,000 -27,855,000 -27,643,000 -24,659,000 -24,068,000 -23,576,000 -24,613,000 -24,387,000 -31,949,000 -34,225,000 -30,793,000 -77,123,000 -42,649,000 -84,581,000 
      net income per share
    		                                            
      basic and diluted
    		                     -0.3 -0.2 -0.2 -0.19 -0.16 -0.16 -0.17 -0.22 -0.22 -0.3 -0.35 -0.35 -0.31 -0.3 -0.29 -0.3 -0.29 -0.39 -0.41 -0.38 -0.97 -0.55 -1.29 
      weighted-average number of shares during the period:
    		                                            
      basic and diluted
    		                     103,550,936 108,246,579 98,769,687 98,472,641 94,210,087 98,331,695 98,594,355 81,261,302 79,132,220 79,204,765 79,107,208 79,036,614 80,583,910 79,440,591 81,440,816 82,138,438 81,979,005 82,154,219 81,959,248 81,574,709 71,519,609 77,837,586 65,789,041 
      change in fair value of warrant liability
    		                                            
      income tax (benefit) expense
    		                                     -149,000 -52,000 -228,000 -143,000    
      interest income
    		                                         25,250 84,000 -15,000 
      fair value adjustment
    		                                         -341,500  -483,000 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 
                                                  
        assets
      		                                            
        current assets:
      		                                            
        cash and cash equivalents
      		205,194,000 88,334,000 60,241,000 137,658,000 60,660,000 143,428,000 111,966,000 130,104,000 133,035,000 265,453,000 177,963,000 43,506,000 88,481,000 104,641,000 104,161,000 61,900,000 36,385,000 181,101,000 64,524,000 83,958,000 44,679,000 11,441,000 27,688,000 102,698,000 16,952,000 15,508,000 18,291,000 17,279,000 22,279,000 16,821,000 15,310,000 16,122,000 11,196,000 23,872,000 20,920,000 39,039,000 13,596,000 8,083,000 31,404,000 38,223,000 63,250,000 175,908,000 358,616,000 120,437,000 
        marketable securities
      		175,685,000 154,484,000 197,572,000 16,000,000 931,000 6,381,000 18,401,000 87,875,000 37,460,000 1,009,000 11,833,000 2,448,000 2,787,000 2,543,000 6,896,000 21,038,000 155,947,000 136,015,000 15,848,000 19,970,000 38,594,000             104,280,000 131,347,000 136,466,000 177,374,000 190,838,000 177,852,000 175,540,000 158,509,000 118,310,000   
        accounts receivable
      		43,271,000 42,571,000 32,016,000 22,126,000 17,029,000 2,360,000 4,175,000 1,033,000                                    45,000 
        inventories
      		547,000 910,000 6,703,000 6,640,000 8,444,000 8,272,000 1,958,000 1,811,000                                     
        due from related parties
      		3,000 46,000 18,000 204,000 424,000 293,000 729,000 1,027,000 2,137,000 2,019,000 2,325,000 2,025,000 1,464,000 1,890,000 1,488,000 1,451,000 3,893,000 1,333,000 1,304,000 2,047,000 2,057,000        86,000 90,000 107,000 54,000 55,000 154,000 61,000 79,000 82,000 1,089,000       
        prepaid expenses and other current assets
      		26,182,000 27,761,000 31,451,000 23,270,000 19,646,000 23,852,000 25,921,000 20,980,000 23,090,000 25,603,000 22,961,000 18,846,000 20,754,000 31,503,000 30,547,000 30,601,000 16,116,000 15,898,000 12,776,000 7,756,000 14,242,000 9,285,000 8,977,000 4,664,000 3,910,000 4,105,000 5,556,000 2,746,000 13,595,000 13,810,000 16,432,000 4,734,000 4,958,000 4,152,000 4,525,000 5,973,000 4,896,000 5,135,000 5,215,000  3,776,000  1,671,000 388,000 
        prepaid expenses – related parties
      		2,071,000 769,000 1,496,000 2,234,000 2,029,000                                        
        total current assets
      		452,953,000 314,875,000 329,497,000 208,132,000 109,163,000 184,586,000 163,150,000 242,830,000 195,722,000 294,084,000 215,082,000 66,825,000 113,486,000 140,577,000 143,092,000 114,990,000 212,341,000 334,347,000 94,452,000 113,731,000 99,572,000 75,498,000 98,018,000 115,287,000 44,125,000 55,757,000 71,613,000 87,048,000 113,430,000 88,772,000 100,570,000 110,093,000 126,802,000 132,458,000 156,853,000 181,557,000 195,948,000 205,145,000 214,471,000 217,959,000 225,535,000 297,540,000 360,287,000 120,870,000 
        property, plant and equipment
      		112,785,000 114,264,000 129,597,000 133,004,000 135,270,000 137,094,000 139,285,000 141,956,000 143,517,000 146,082,000 152,000,000 151,487,000 154,165,000 143,659,000 130,441,000 119,445,000 105,217,000 82,863,000 69,878,000 89,023,000 80,875,000 53,927,000 55,864,000 58,615,000 58,539,000 60,501,000 62,157,000 65,089,000 67,921,000 76,885,000 77,273,000 78,211,000 76,826,000 76,726,000 74,471,000 60,218,000 22,558,000 18,906,000       
        goodwill and intangible assets
      		12,885,000 13,953,000 14,475,000 14,977,000 15,443,000 15,933,000 16,479,000                                      
        long-term inventories
      		18,856,000 13,508,000                                           
        convertible note receivable
      		 7,380,000 7,317,000 7,254,000 7,192,000 7,130,000 7,067,000 7,004,000 6,942,000 6,879,000 6,816,000 6,753,000 6,691,000 6,629,000 6,566,000 6,503,000 6,441,000 6,379,000 6,316,000 6,253,000 6,191,000                        
        operating lease right-of-use assets
      		20,573,000 19,808,000 19,273,000 20,103,000 16,482,000 33,363,000 34,946,000 33,817,000 35,197,000 36,543,000 35,810,000 42,555,000 44,191,000 45,788,000 46,429,000 48,103,000 35,897,000 36,304,000 34,099,000 28,230,000 18,447,000 13,463,000 14,602,000 10,407,000 11,055,000 11,729,000 12,407,000 12,513,000 13,155,000                
        operating lease right-of-use assets, net – related parties
      		12,461,000 13,202,000 13,922,000 14,620,000 15,298,000                                        
        other assets
      		15,746,000 4,530,000 4,473,000 3,553,000 4,533,000 4,827,000 3,643,000 2,660,000 2,729,000 2,880,000 3,427,000 3,774,000 4,545,000  5,133,000 6,024,000 6,477,000  7,442,000 6,797,000 1,905,000 1,121,000 2,029,000 2,602,000 4,051,000 4,386,000 3,284,000 310,000 314,000 1,527,000 1,583,000 354,000 366,000 330,000 324,000 335,000 661,000 788,000 862,000 1,140,000 1,696,000 1,359,000 1,326,000 3,757,000 
        other assets – related parties
      		378,000 378,000 433,000 433,000 378,000                                        
        total assets
      		646,637,000 501,898,000 518,987,000 402,076,000 303,759,000 382,933,000 364,570,000 444,325,000 400,679,000 504,452,000 432,419,000 291,227,000 343,400,000 362,356,000 352,943,000 317,717,000 389,587,000 468,910,000 214,421,000 246,301,000 209,428,000 151,858,000 180,535,000 196,164,000 127,023,000 143,123,000 160,207,000 175,696,000 208,261,000 181,950,000 201,641,000 211,433,000 229,845,000 250,440,000 277,737,000 301,620,000 303,675,000 317,496,000 332,411,000 342,935,000 357,428,000 366,849,000 370,191,000 132,557,000 
        liabilities and stockholders’ deficit
      		                                            
        current liabilities:
      		                                            
        accounts payable
      		11,192,000 6,978,000 5,773,000 7,419,000 13,501,000 6,725,000 9,945,000 20,317,000 13,869,000 9,195,000 19,818,000 25,488,000 33,573,000 21,016,000 20,237,000 18,053,000 9,832,000 11,418,000 15,120,000 19,153,000 20,097,000 4,101,000 6,160,000 3,971,000 3,148,000 1,749,000 2,115,000 1,927,000 2,804,000 2,793,000 3,525,000 5,502,000 3,566,000 5,865,000 9,485,000 4,271,000 4,280,000 4,045,000 2,245,000 3,303,000 1,105,000 2,085,000 4,947,000 3,180,000 
        accrued expenses and other liabilities
      		48,204,000 46,838,000 43,602,000 35,705,000 27,889,000 40,580,000 43,596,000 35,344,000 32,712,000 42,708,000 64,871,000 62,335,000 54,118,000 41,825,000 46,220,000 52,351,000 62,468,000 51,387,000 38,519,000 36,134,000 36,793,000                        
        operating lease liabilities
      		4,690,000 4,291,000 3,770,000 3,682,000 3,876,000 7,466,000 7,033,000 6,249,000 6,082,000 5,244,000 4,363,000 5,984,000 2,844,000 2,650,000 1,365,000 1,404,000 3,507,000 3,011,000 3,072,000 2,430,000 5,156,000 5,500,000 5,351,000                      
        operating lease liabilities – related parties
      		2,936,000 3,244,000 3,546,000 3,710,000 3,584,000                                        
        due to related parties
      		930,000 403,000 443,000 128,000 355,000 173,000 386,000 200,000 1,096,000 1,136,000 1,272,000 1,159,000 2,932,000 3,469,000 3,018,000 4,158,000 5,595,000 3,943,000 8,697,000 16,711,000 17,817,000 5,269,000 1,356,000 2,228,000 853,000 486,000 868,000 957,000 1,531,000 1,696,000 2,175,000 1,806,000 2,456,000 2,363,000 1,986,000 2,216,000 2,124,000 1,753,000 1,853,000 1,727,000 1,674,000 1,352,000 610,000  
        total current liabilities
      		67,952,000 61,754,000 57,134,000 50,644,000 49,205,000 54,944,000 60,960,000 62,110,000 53,759,000 58,283,000 90,324,000 613,478,000 564,945,000 500,861,000 70,840,000 376,050,000 381,014,000 368,995,000 65,408,000 74,428,000 79,863,000 24,651,000 20,663,000 17,049,000 14,248,000 11,559,000 12,519,000 12,430,000 27,701,000 27,260,000 30,404,000 20,192,000 19,398,000 20,868,000 28,674,000 36,878,000 14,201,000 12,553,000 10,232,000 10,045,000 7,858,000 6,148,000 6,683,000  
        related-party convertible note payable, at fair value
      		678,386,000 477,093,000 500,804,000 492,084,000 485,717,000 461,877,000                                       
        revenue interest liability
      		404,299,000 324,615,000 316,145,000 307,049,000 296,287,000 284,404,000 273,657,000 263,342,000 163,416,000 155,415,000                                   
        operating lease liabilities, less current portion
      		20,062,000 19,732,000 19,805,000 20,798,000 17,077,000 34,823,000 36,761,000 36,427,000 38,199,000 39,942,000 39,313,000 44,558,000 46,289,000 47,951,000 49,561,000 50,648,000 36,251,000 37,068,000 34,642,000 29,116,000 16,554,000 9,814,000 11,250,000                      
        operating lease liabilities, less current portion – related parties
      		13,085,000 13,715,000 14,325,000 15,042,000 16,020,000                                        
        derivative liabilities
      		23,314,000 19,722,000 18,322,000 18,611,000 20,542,000 25,800,000 19,223,000 20,807,000 37,930,000 35,333,000                                   
        warrant liabilities
      		308,193,000 84,417,000 115,160,000 66,957,000 9,023,000 8,575,000 18,308,000 65,395,000 109,987,000 118,770,000 39,370,000 27,799,000 17,780,000                                
        other liabilities
      		472,000 424,000 702,000 710,000 370,000 639,000 705,000 704,000 1,285,000 1,109,000 467,000 473,000 462,000 457,000 569,000 290,000 288,000 249,000 905,000 920,000 891,000          24,000 44,000 65,000 89,000 341,000 370,000 216,000 240,000 22,000 26,000     
        total liabilities
      		1,515,763,000 1,001,472,000 1,042,397,000 971,895,000 894,241,000 871,062,000 1,108,732,000 1,141,703,000 1,091,662,000 1,090,389,000 843,064,000 936,410,000 875,116,000 812,176,000 782,024,000 739,691,000 727,143,000 712,823,000 404,365,000 404,886,000 394,764,000 34,465,000 31,913,000 26,511,000 24,428,000 22,444,000 24,251,000 24,427,000 40,453,000 35,944,000 39,555,000 29,802,000 29,485,000 31,596,000 40,033,000 48,696,000 25,306,000 24,078,000 21,520,000 15,578,000 12,928,000 10,854,000 7,260,000 6,039,000 
        marketable securities, noncurrent
      		         891,000 817,000 841,000 820,000 840,000 811,000 914,000 865,000 822,000 802,000 822,000 1,000,000             29,600,000 34,198,000 47,054,000 71,487,000 87,571,000 94,655,000 107,933,000 116,197,000 55,135,000   
        related-party nonconvertible note, net of discount
      		      111,143,000 108,811,000 106,637,000 104,586,000                                   
        related-party convertible notes and accrued interest, net of discount
      		      587,975,000 584,107,000 580,449,000 576,951,000 165,289,000 250,102,000 245,640,000                                
        commitments and contingencies
      		                                            
        stockholders’ deficit:
      		                                            
        common stock, 0.0001 par value...
      		     85,000   68,000 67,000 67,000 44,000 43,000 42,000 40,000 40,000 40,000 40,000 39,000 39,000 38,000 11,000 11,000 11,000 10,000 10,000   10,000 8,000 8,000 8,000 8,000 8,000 8,000 8,000 8,000 8,000 8,000 8,000 8,000 8,000 8,000 7,000 
        additional paid-in capital
      		     2,884,867,000   2,403,720,000 2,374,620,000 2,315,716,000 1,990,590,000 1,965,838,000 1,930,936,000 1,843,724,000 1,739,590,000 1,729,430,000 1,719,704,000 1,682,072,000 1,625,018,000 1,508,958,000 872,078,000 871,170,000 870,408,000 783,287,000 782,965,000 782,549,000 782,312,000 781,790,000 741,246,000 739,839,000 735,849,000 726,953,000 717,930,000 709,353,000 700,639,000 691,229,000 680,757,000 669,624,000 651,330,000 625,200,000 606,555,000 535,696,000 256,515,000 
        accumulated deficit
      		     -3,375,248,000   -3,095,793,000 -2,961,684,000 -2,728,292,000 -2,632,710,000 -2,494,831,000 -2,378,488,000 -2,270,273,000 -2,159,335,000 -2,064,747,000 -1,961,921,000 -1,870,662,000 -1,783,033,000 -1,694,745,000 -754,574,000 -722,442,000 -700,666,000 -680,574,000 -662,191,000 -646,550,000 -630,969,000 -613,786,000 -594,981,000 -577,413,000 -553,778,000 -526,046,000 -498,713,000 -471,455,000 -447,486,000 -412,628,000 -387,063,000 -358,876,000 -324,405,000 -281,026,000 -250,376,000 -172,723,000 -130,004,000 
        accumulated other comprehensive income
      		     1,198,000   -7,000 10,000 792,000 -40,000 -33,000 183,000 -190,000 -110,000 -367,000 4,000 53,000 37,000 -38,000                  135,000 424,000 318,000    
        total immunitybio stockholders’ deficit
      		     -489,098,000   -692,012,000 -586,987,000 -411,717,000 -642,116,000 -528,983,000 -447,327,000 -426,699,000 -419,815,000 -335,644,000 -242,173,000 -188,498,000 -157,939,000 -185,787,000                        
        noncontrolling interests
      		     969,000   1,029,000 1,050,000 1,072,000 -3,067,000 -2,733,000 -2,493,000 -2,382,000 -2,159,000 -1,912,000 -1,740,000 -1,446,000 -646,000 451,000                        
        total stockholders’ deficit
      		     -488,129,000   -690,983,000 -585,937,000 -410,645,000 -645,183,000 -531,716,000 -449,820,000 -429,081,000 -421,974,000 -337,556,000 -243,913,000 -189,944,000 -158,585,000 -185,336,000                        
        total liabilities and stockholders’ deficit
      		     382,933,000   400,679,000 504,452,000 432,419,000 291,227,000 343,400,000 362,356,000 352,943,000 317,717,000 389,587,000 468,910,000 214,421,000 246,301,000 209,428,000                        
        intangible assets
      		       16,058,000 16,572,000 17,093,000 18,467,000 18,992,000 19,502,000  20,471,000 21,738,000 22,349,000             565,000 1,130,000 1,695,000 2,260,000 2,826,000 3,391,000 3,956,000 4,521,000 5,086,000 5,948,000 6,396,000 6,844,000 7,292,000 7,164,000 7,620,000 
        related-party promissory notes, net of discounts and deferred issuance costs
      		           481,894,000 441,628,000 431,901,000                               
        related-party promissory notes, less current portion
      		          480,020,000     312,541,000 309,428,000                            
        related-party convertible note payable at fair value
      		          28,281,000                                  
        related-party convertible note at fair value
      		           36,618,000 29,850,000                                
        intangible asset
      		             20,003,000    1,420,000 1,432,000 1,445,000 1,438,000                        
        investment and other assets
      		             4,860,000    6,775,000                           
        related-party convertible notes and accrued interest, net of discount, less current portion
      		             241,271,000 287,761,000                              
        warrant liability
      		             21,636,000                               
        related-party promissory note, net of deferred issuance costs
      		                                            
        related-party promissory notes, net of discount, less current portion
      		              373,293,000                              
        related-party promissory notes, current portion
      		               300,084,000 299,612,000                            
        deferred income tax liability
      		               162,000 162,000  170,000 170,000 170,000                        
        non-marketable equity investment
      		                                            
        related-party notes payable
      		                 299,236,000 303,240,000 300,252,000 297,286,000                        
        related-party notes payable, less current portion
      		                 306,349,000                           
        deferred tax liability
      		                 162,000             122,000 250,000 374,000 498,000 681,000 779,000 903,000 996,000 883,000 969,000 1,072,000 1,165,000   
        marketable debt securities, available-for-sale
      		                     54,772,000 61,353,000 7,925,000 23,263,000 36,144,000 47,766,000 66,773,000 76,270,000 57,328,000 67,998,000 88,822,000             
        marketable debt securities, noncurrent
      		                      769,000   1,497,000 1,493,000 1,483,000 4,190,000 5,701,000 12,585,000 12,580,000 15,091,000            
        equity investment
      		                     7,849,000 9,253,000 9,253,000 9,253,000 9,253,000     8,500,000 8,500,000 8,500,000            
        liabilities and stockholders’ equity
      		                                            
        accrued expenses
      		                     8,343,000 5,497,000 7,449,000 6,634,000 5,343,000 5,251,000 6,466,000 20,242,000 21,104,000 22,785,000 11,517,000 12,077,000 11,267,000 15,838,000 14,381,000 6,858,000 5,864,000 5,910,000 4,724,000 4,716,000 2,575,000 1,126,000 2,618,000 
        other current liabilities
      		                     1,438,000 2,299,000 3,401,000 3,613,000 3,981,000 4,285,000 3,080,000 3,124,000 1,667,000 1,919,000 1,367,000 1,299,000 1,373,000 1,365,000 1,130,000 939,000 891,000 224,000 291,000 363,000 136,000   
        stockholders’ equity:
      		                                            
        accumulated other comprehensive loss
      		                     -122,000 -117,000 -100,000 -128,000 -105,000 -53,000 -84,000 -206,000 -267,000 -348,000 -448,000 -555,000 -381,000 -202,000 -237,000 -240,000 -284,000    -192,000 -50,000  
        total stockholders’ equity
      		                     117,393,000 148,622,000 169,653,000 102,595,000 120,679,000 135,956,000 151,269,000 167,808,000 146,006,000 162,086,000 181,631,000 200,360,000 218,844,000 237,704,000 252,924,000 278,369,000 293,418,000 310,891,000 327,357,000 344,500,000 355,995,000 362,931,000 126,518,000 
        total liabilities and stockholders’ equity
      		                     151,858,000 180,535,000 196,164,000 127,023,000 143,123,000 160,207,000 175,696,000 208,261,000 181,950,000 201,641,000 211,433,000 229,845,000 250,440,000 277,737,000 301,620,000 303,675,000 317,496,000 332,411,000 342,935,000 357,428,000 366,849,000 370,191,000 132,557,000 
        operating lease liability, less current portion
      		                       9,462,000 10,180,000 10,885,000 11,732,000 11,997,000 12,752,000                
        notes receivable, held-to-maturity
      		                             723,000 723,000              
        financing obligation, less current portion
      		                             5,945,000 6,108,000 6,267,000 1,663,000 1,741,000 1,814,000 1,885,000 1,955,000 2,025,000 2,390,000      
        deferred rent
      		                             2,739,000 2,897,000 3,049,000 3,188,000 3,325,000 3,461,000 3,595,000 2,374,000 2,426,000 2,488,000 1,924,000 1,344,000 845,000 342,000  
        investment in equity securities
      		                          9,253,000 9,253,000 9,251,000 8,500,000               
        common stock, 0.0001 par value per share...
      		                          10,000 10,000                 
        restricted cash
      		                           250,000 1,200,000                
        stockholders’ equity
      		                                            
        build-to-suit liability, less current portion
      		                                4,797,000 4,909,000 5,062,000 5,189,000 5,475,000 5,651,000 5,313,000 2,417,000 2,451,000    
        note receivable, held-to-maturity
      		                               361,000             
        marketable debt securities
      		                                110,593,000            
        cost method investment
      		                                 8,500,000 8,500,000 8,500,000 8,500,000        
        deferred revenue
      		                                 166,000   182,000 187,000 192,000 197,000 203,000 228,000 235,000 241,000 
        financing obligation
      		                                   14,880,000         
        property and equipment
      		                                      16,475,000 9,507,000 7,156,000 5,523,000 1,414,000 310,000 
        receivables, net, prepaid expenses and other current assets
      		                                       4,196,000  3,322,000   
        liabilities and stockholders' equity
      		                                            
        build-to-suit lease liability, less current portion
      		                                         2,468,000   
        stockholders' equity
      		                                            
        class a common stock, 0.0001 par value...
      		                                            
        investment in inex bio, inc.
      		                                            
        notes payable
      		                                            
        warrant derivative liability
      		                                            
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 
                                                   
          operating activities:
        		                                           
          net loss
        		-632,797,000 -61,958,000 -67,274,000 -92,574,000 -129,666,000 -59,179,000 -85,752,000 -134,584,000 -134,130,000 -233,414,000 -95,642,000 -138,213,000 -116,583,000    -102,998,000        -18,383,000                   
          adjustments to reconcile net loss to net cash from operating activities:
        		                                           
          change in fair value of warrant liabilities
        		295,413,000 -30,743,000 -14,905,000 -3,889,000 448,000 -9,733,000 -31,324,000 19,300,000 1,802,000 79,400,000 -14,265,000 10,019,000 -27,554,000                               
          change in fair value of related-party convertible note
        		236,625,000 191,000 1,169,000 -1,169,000 42,582,000                                       
          non-cash interest expense related to revenue interest liability
        		8,317,000 8,634,000 9,310,000 10,019,000 13,266,000                                       
          stock-based compensation expense
        		8,169,000 8,746,000 8,878,000 9,648,000 9,537,000 9,038,000 7,489,000 9,639,000 8,266,000 12,774,000 14,449,000 11,062,000 10,878,000 9,350,000 10,630,000 10,175,000 10,024,000 10,180,000 13,840,000 17,863,000 15,298,000 667,000 711,000 316,000 445,000 477,000 277,000 522,000 1,351,000 1,407,000 3,968,000 8,934,000 9,073,000 8,884,000 8,714,000 9,381,000 10,018,000 11,266,000 18,669,000 23,382,000 20,535,000 70,554,000 36,103,000 
          write-off of convertible note receivable
        		7,442,000                                           
          depreciation and amortization
        		4,380,000 3,865,000 3,951,000 3,880,000 3,829,000 4,138,000 4,455,000 4,406,000 4,555,000 4,564,000 4,585,000 4,682,000 4,681,000 5,226,000 4,500,000 4,444,000 4,090,000 3,595,000 3,687,000 3,984,000 2,972,000 2,283,000 2,380,000 2,267,000 2,217,000 2,209,000 2,202,000 2,206,000 2,395,000 2,787,000 2,776,000 2,369,000 1,623,000 1,569,000 1,461,000 1,374,000 1,162,000 1,839,000 770,000 513,000 485,000 405,000 25,000 
          accretion of discounts on marketable debt securities, available-for-sale
        		-1,526,000                                           
          realized gain on instrument-specific credit risk
        		-1,425,000                                           
          change in fair value of derivative liabilities
        		-1,108,000 1,400,000 -289,000 -1,931,000 -5,578,000 6,607,000 -1,614,000 -21,194,000 2,724,000                                   
          non-cash lease expense related to operating lease right-of-use assets
        		956,000 842,000 830,000 905,000 925,000 1,615,000 1,415,000 1,380,000 1,346,000 1,326,000 1,553,000 1,636,000 1,597,000 1,652,000 1,475,000 1,487,000 1,318,000 1,384,000 1,231,000 714,000 1,555,000 1,140,000 968,000 648,000 674,000 679,000 659,000                 
          non-cash lease expense related to operating lease right-of-use assets – related parties
        		741,000 720,000 698,000 678,000 658,000                                       
          non-cash interest items
        		-62,000 -63,000 -63,000 -62,000 -62,000 1,337,000 -62,000 -62,000 -63,000 201,000 3,962,000 2,521,000 2,505,000 -2,024,000 6,848,000 3,524,000 3,398,000   2,813,000 3,435,000 37,000 -398,000 93,000 17,000 73,000 110,000 158,000 -95,000 -32,000 232,000 -58,000 149,000 72,000 178,000 217,000 253,000 -300,000 243,000 -221,000 -295,000   
          other
        		16,000 82,000 35,000 211,000 242,000 -37,000 52,000 20,000 74,000 52,000 -582,000 12,000 111,000 400,000 -152,000 -823,000 848,000    -125,000                       
          changes in operating assets and liabilities:
        		                                           
          accounts receivable
        		-700,000 -10,555,000 -9,890,000 -5,097,000 -14,669,000 1,815,000 -3,142,000                                   0 -25,000 
          inventories
        		-4,985,000 -7,894,000 -63,000 1,804,000 -172,000 -6,314,000 -147,000                                     
          prepaid expenses and other current assets
        		1,861,000 2,335,000 -5,578,000 -3,939,000 114,000 1,333,000 -2,778,000 1,514,000 1,634,000 -3,505,000 -1,777,000 1,551,000 9,689,000 -2,137,000 54,000 -14,256,000 -218,000 -2,674,000 -4,995,000 6,354,000 -934,000 963,000 -3,218,000 683,000 244,000     2,634,000 -11,908,000 303,000 -847,000 732,000          
          prepaid expenses – related parties
        		-1,302,000 727,000 738,000 -205,000 951,000                                       
          other assets
        		-1,052,000 -16,000 -324,000 1,227,000 -84,000 -1,034,000 -255,000 49,000 132,000 528,000 338,000 752,000 295,000  1,439,000 598,000 101,000  -645,000 -4,892,000 693,000 -455,000 -51,000 -168,000 335,000     66,000 -1,229,000   -6,000 12,000 326,000 126,000 78,000 237,000 175,000 -337,000 -33,000 2,431,000 
          accounts payable
        		3,901,000 979,000 -1,392,000 -6,216,000 6,439,000 -3,214,000 -8,922,000 4,655,000 4,314,000 -2,877,000 -2,730,000 -1,537,000 668,000 437,000 1,028,000 5,740,000 795,000 -3,547,000 -2,770,000 -3,897,000 6,497,000 -2,111,000 3,078,000 -95,000 1,270,000 -301,000 407,000 -735,000 670,000 -1,034,000 -1,941,000 1,758,000 117,000 -1,343,000 2,560,000 -1,792,000 725,000 567,000 237,000 821,000 -737,000 -3,188,000 1,767,000 
          accrued expenses and other liabilities
        		3,137,000 1,925,000 5,469,000 8,723,000 -12,933,000 -2,114,000 6,226,000 3,297,000 -8,917,000 -19,516,000 -1,659,000 9,274,000 18,590,000 -3,151,000 6,651,000 -10,289,000 10,891,000 4,558,000 4,445,000 -1,928,000 -1,893,000 2,112,000 103,000 474,000 997,000 -398,000 843,000 -13,262,000 797,000 -1,911,000 14,016,000 -1,275,000 1,878,000 147,000 658,000 -1,538,000 434,000 -327,000 816,000 402,000 1,236,000   
          due to and due from related parties
        		570,000 -68,000 501,000 -7,000 51,000                                       
          operating lease liabilities
        		-992,000 -929,000 -912,000 -992,000 -916,000 -1,537,000 -1,516,000 -1,522,000 -898,000 -549,000 -1,108,000 190,000 -1,511,000 -2,013,000 -112,000 -1,855,000 -339,000 -517,000 -670,000 -1,503,000 -1,474,000 -1,287,000 -1,118,000 -778,000 -758,000 -737,000                  
          operating lease liabilities – related parties
        		-938,000 -912,000 -881,000 -852,000 -816,000                                       
          net cash from operating activities
        		-75,359,000 -70,378,000 -68,907,000 -79,746,000 -85,905,000 -85,144,000 -98,763,000 -100,347,000 -106,982,000 -115,271,000 -87,403,000 -79,773,000 -84,310,000 -90,727,000 -80,600,000 -91,252,000 -74,930,000 -71,639,000 -72,716,000 -69,595,000 -60,469,000 -23,056,000 -18,280,000 -16,521,000 -12,596,000 -14,885,000 -16,572,000 -16,827,000 -13,078,000 -14,033,000 -17,571,000 -16,266,000 -15,511,000 -13,640,000 -10,133,000 -14,950,000 -10,057,000 -10,753,000 -10,683,000 -8,301,000 -8,856,000 -11,085,000 -4,178,000 
          capital expenditures
        		-1,776,000 -903,000 -741,000 -1,081,000 -1,121,000 -2,111,000 -2,792,000 -724,000 -1,261,000 -7,955,000 -5,675,000 -8,526,000 -8,428,000 -18,931,000 -15,935,000 -15,949,000 -27,347,000 -10,403,000 -8,032,000 -8,045,000 -7,083,000 -401,000 -1,698,000 -394,000 -146,000 -680,000 -413,000 -985,000 -2,104,000 -2,045,000 -3,663,000 -2,492,000 -4,902,000 -11,433,000 -10,717,000 -8,156,000 -4,509,000 0 -3,079,000 -1,056,000 -1,067,000 -955,000 -1,134,000 
          free cash flows
        		-77,135,000 -71,281,000 -69,648,000 -80,827,000 -87,026,000 -87,255,000 -101,555,000 -101,071,000 -108,243,000 -123,226,000 -93,078,000 -88,299,000 -92,738,000 -109,658,000 -96,535,000 -107,201,000 -102,277,000 -82,042,000 -80,748,000 -77,640,000 -67,552,000 -23,457,000 -19,978,000 -16,915,000 -12,742,000 -15,565,000 -16,985,000 -17,812,000 -15,182,000 -16,078,000 -21,234,000 -18,758,000 -20,413,000 -25,073,000 -20,850,000 -23,106,000 -14,566,000 -10,753,000 -13,762,000 -9,357,000 -9,923,000 -12,040,000 -5,312,000 
          investing activities:
        		                                           
          purchases of marketable debt securities, available-for-sale
        		-139,093,000 -45,626,000 -180,586,000 -15,061,000 -100,000 -6,089,000 0 -85,766,000 -48,363,000 -166,000 -9,956,000 -78,000 -158,000 -19,000 -86,000 -125,000 -34,082,000 -139,001,000 -2,483,000 -175,000 -91,000 -5,991,000 -70,791,000 -4,490,000 -10,300,000 -9,787,000 -10,042,000 -16,516,000 -50,273,000 -12,513,000 -28,754,000             
          proceeds from maturities of marketable debt securities, available-for-sale
        		79,382,000 59,547,000 0 0 5,350,000 18,034,000                                      
          proceeds from sales of marketable debt securities, available-for-sale
        		39,848,000                                           
          cash paid for other equity securities
        		-10,000,000                                           
          purchases of property, plant and equipment
        		-1,776,000 -903,000 -741,000 -1,081,000 -1,121,000 -2,111,000 -2,792,000 -724,000 -1,261,000 -7,955,000 -5,675,000 -8,526,000 -8,428,000 -18,931,000 -15,935,000 -15,949,000 -27,347,000 -10,403,000 -8,032,000 -8,045,000 -7,083,000 -401,000 -1,698,000 -394,000 -146,000 -680,000 -413,000 -985,000 -2,104,000 -2,045,000 -3,663,000 -2,492,000 -4,902,000 -11,433,000 -10,717,000 -8,156,000 -4,509,000       
          software development costs
        		-11,000 -372,000                                          
          net cash from investing activities
        		-31,650,000 43,573,000 -181,361,000 -16,142,000 4,129,000 9,834,000 65,032,000 -51,490,000 -35,622,000 2,249,000 -15,631,000 -8,604,000 -8,484,000 -18,894,000 -1,168,000 116,672,000 -69,313,000 -137,802,000 10,582,000 10,489,000 31,845,000 6,568,000 -56,247,000 14,927,000 14,163,000 12,163,000 17,374,000 11,378,000 -19,459,000 15,914,000 16,874,000 21,393,000 2,920,000 19,734,000 6,961,000 56,819,000 16,038,000 -8,464,000 6,855,000 -10,151,000 -101,912,000 -171,979,000 -672,000 
          financing activities:
        		                                           
          proceeds from equity offerings, net of issuance costs
        		102,227,000                                         263,000 245,213,000 
          proceeds from the ripa, net of issuance costs
        		75,000,000     0 0                                     
          proceeds from exercises of warrants
        		53,542,000     0 15,617,000 43,548,000 14,116,000                                   
          net share settlement for rsus vesting
        		-6,994,000 -590,000 -151,000 -322,000 -1,202,000 -803,000 -299,000 -496,000 -3,867,000 -1,562,000 -1,464,000 -60,000 -357,000 -219,000 -10,000 -15,000 -372,000  -960,000 0 -2,624,000                       
          proceeds from exercises of stock options
        		971,000 0 0 0 220,000 0 286,000   1,000 32,000 135,000 126,000 0 0 0 74,000 351,000 678,000 3,311,000 1,121,000 259,000 353,000                     
          principal payments on premium financing
        		-868,000                                           
          proceeds from borrowings
        		61,000                                           
          principal payments of finance leases
        		-13,000 -12,000 -12,000   0 -22,000 -21,000 -21,000 -20,000 -19,000 -19,000 -19,000 -18,000                              
          net cash from financing activities
        		223,926,000 54,894,000 173,519,000 172,810,000 -982,000 106,929,000 15,582,000 148,894,000 10,225,000 200,539,000 237,502,000 43,412,000 76,888,000 109,940,000 123,986,000 -15,000 -298,000 325,953,000 42,656,000 98,337,000 38,497,000 241,000 -483,000 87,340,000 -123,000 -61,000 -40,000 -501,000 39,195,000 -370,000 -115,000 -201,000 -85,000 -3,142,000 -14,947,000 -16,426,000 -468,000 -4,104,000 -2,991,000 -6,575,000 -1,890,000 306,000 243,079,000 
          effect of exchange rate changes on cash and cash equivalents, and restricted cash
        		122,000 5,000 -56,000 76,000 -10,000 -7,000                                      
          net change in cash and cash equivalents, and restricted cash
        		117,039,000 28,094,000 -76,805,000 76,998,000 -82,768,000 31,612,000                                      
          cash and cash equivalents, and restricted cash, beginning of period
        		89,431,000  0 0 143,912,000                                       
          cash and cash equivalents, and restricted cash, end of period
        		206,470,000  -76,805,000 76,998,000 61,144,000                                       
          loss due to write-off of fixed assets
        		                                           
          transaction costs allocated to warrant liabilities
        		 0 2,063,000       0 1,026,000 0 984,000                               
          amortization of related-party notes discounts
        		     5,007,000 6,199,000 5,832,000 5,549,000 7,118,000 11,454,000 12,288,000 11,536,000                               
          unrealized losses on equity securities
        		    1,000 112,000 505,000   740,000 593,000                                 
          impairment of intangible assets
        		             0                              
          acquisition of a business, net of transaction costs
        		     0                                      
          cash paid for other investments
        		     0                                      
          proceeds from equity offerings, net of discounts and issuance costs
        		     107,732,000 0   15,920,000 37,463,000 -110,000 47,288,000                               
          proceeds from short-term borrowings
        		                                           
          proceeds from exercise of oberland stock option, net of commissions
        		     0 0                                     
          proceeds from issuance of related-party promissory notes, net of issuance costs paid
        		          199,000,000   49,750,000                              
          proceeds from stock option issuance in connection with the ripa, net of transaction costs
        		                                           
          cash and cash equivalents, and restricted cash, beginning of year
        		                                           
          cash and cash equivalents, and restricted cash, end of year
        		                                           
          accretion of discounts on marketable debt securities
        		  -978,000 -11,000 -52,000 -24,000 -580,000 -394,000 -491,000                                   
          proceeds from sales of marketable debt securities
        		      20,040,000              7,094,000                       
          payment of revenue interest liability
        		        -3,000                                   
          change in fair value of convertible note
        		         36,952,000 -7,517,000                                 
          non-cash interest expense related to the revenue interest liability
        		     10,289,000 10,504,000 9,207,000 8,004,000                                   
          impairment of fixed assets
        		                                           
          related parties
        		     223,000 484,000 214,000 -158,000 170,000 -67,000 -1,171,000 -61,000 414,000 2,220,000 -2,241,000 -1,618,000 -5,473,000 -7,293,000 -18,000 2,597,000                       
          proceeds from sales of marketable debt and equity securities
        		         270,000 0 0 102,000 56,000 99,000   195,000 -1,000                         
          purchase of intangible assets
        		             0 0 0 -21,229,000                           
          investment in joint venture – an equity method investment
        		             0 0 0 -1,000,000                           
          proceeds from issuance of related-party promissory notes net of issuance costs paid
        		                                           
          proceeds from stock issuance in connection with the ripa, net of transaction costs
        		                                           
          payment for contingent consideration
        		             0    0                          
          maturities of marketable debt securities, available-for-sale
        		       35,000,000 13,021,000                                   
          effect of exchange rate changes on cash, cash equivalents, and restricted cash
        		       12,000 -39,000 -27,000 -1,000 -10,000 -254,000 161,000 43,000 255,000 -175,000 65,000 44,000 48,000 -109,000                       
          net change in cash, cash equivalents, and restricted cash
        		       -2,931,000 -132,418,000 87,490,000 134,467,000 -44,975,000 -16,160,000 480,000 42,261,000 25,660,000 -144,716,000 116,577,000 -19,434,000 39,279,000 9,764,000                       
          cash, cash equivalents, and restricted cash, beginning of period
        		       0 265,787,000  0 0 104,965,000  0 0 181,280,000  0 0 35,094,000  0 0 15,687,000                   
          cash, cash equivalents, and restricted cash, end of period
        		       -2,931,000 133,369,000  134,467,000 -44,975,000 88,805,000  42,261,000 25,660,000 36,564,000  -19,434,000 39,279,000 44,858,000  -75,010,000 85,746,000 17,131,000  762,000 -5,950,000 23,658,000 1,511,000 -812,000             
          unrealized (gains) on equity securities
        		        -725,000    -135,000                               
          proceeds from sale of marketable debt securities
        		        981,000                                   
          amortization of premiums, net of discounts, on marketable debt securities
        		                                           
          proceeds from sales of property, plant and equipment
        		                 0            392,000              
          maturities of marketable debt securities, available for sale
        		             0 14,754,000 99,089,000 14,345,000 11,407,000 600,000                         
          proceeds from the ripa, net of transaction costs
        		                                           
          sale of assets to an entity under common control
        		                 0                          
          cash, cash equivalents, and restricted cash, beginning of year
        		                                           
          cash, cash equivalents, and restricted cash, end of year
        		                                           
          amortization of net premiums, net of discounts, on marketable debt securities
        		                                           
          issuance of common stock under “at-the-market” offering, net of offering costs
        		          2,490,000                                 
          proceeds from issuance of related-party convertible promissory notes, net of issuance costs paid
        		            29,850,000                               
          change in fair value of warrant liability
        		                                           
          transaction costs allocated to warrant liability
        		                                           
          unrealized loss on non-marketable equity investment
        		                                           
          deferred tax
        		                                           
          investment and other assets
        		                                           
          net income
        		              -111,161,000     -89,385,000 -80,481,000        -17,885,000 -17,340,000 -23,635,000 -27,732,000 -27,519,000 -24,487,000 -23,969,000 -23,452,000 -24,515,000 -24,238,000 -31,897,000 -34,024,000 -30,650,000 -76,821,000 -42,649,000 
          adjustments to reconcile net income to net cash from operating activities:
        		                                           
          amortization of net premiums and discounts on marketable debt securities
        		              10,000    13,000 23,000 225,000 369,000 334,000 46,000 45,000                   
          unrealized (gains) losses on equity securities
        		                    -8,834,000                       
          proceeds from equity offering, net of issuance costs paid
        		                 27,582,000 41,922,000    -514,000                     
          loss on equity method investment
        		               3,900,000 197,000                           
          unrealized losses (gains) on equity securities
        		                                           
          unrealized gains on equity securities
        		                -1,419,000  6,008,000                         
          payment to precision biologics to facilitate deconsolidation
        		                                           
          purchase of non-marketable equity investment
        		                                           
          net share settlement for rsus vesting and warrant exercise
        		                                           
          repurchase of common stock
        		                          0          -1,050,000 -3,949,000 -2,574,000 -6,774,000 -2,550,000  0 
          non-cash interest expense
        		                                           
          realized gains on sales of equity securities
        		                  0                         
          change in fair value of contingent consideration
        		                                           
          proceeds from issuance of related-party promissory notes
        		                  0 0 40,000,000                       
          change in fair value of contingent consideration obligations
        		                                           
          maturities of marketable debt securities
        		                    31,925,000 11,270,000                      
          unrealized loss on equity investment
        		                                           
          losses (gains) on sales of marketable debt securities
        		                                           
          loss on disposal of assets
        		                             75,000 44,000 54,000 36,000 0    0 0 3,000 15,000   
          loss on impairment of assets
        		                                           
          deferred income tax benefit
        		                             -122,000 -128,000 -124,000 -124,000 -182,000 -98,000 -124,000 -93,000 -152,000 -50,000 -228,000 -145,000   
          due to related parties
        		                     3,943,000 705,000 86,000 300,000 -254,000 -157,000 -520,000 -162,000 -503,000 326,000 -528,000 20,000 803,000 -670,000 115,000 1,314,000 -123,000 126,000 53,000 322,000 742,000  
          deferred rent
        		                                      619,000 531,000 500,000 508,000  
          purchases of debt securities, held-to-maturity
        		                             0              
          purchases of investments in equity securities
        		                                           
          sales of marketable debt securities
        		                     1,690,000                      
          proceeds from equity offering, net of issuance cost paid
        		                                           
          principal payments of financing obligations
        		                                -65,000           
          repurchases of common stock with commissions
        		                                           
          net share settlement for restricted stock unit vesting and warrant and option exercises
        		                                           
          net decrease in cash, cash equivalents, and restricted cash
        		                                           
          cash, cash equivalents and restricted cash, beginning of period
        		                         0 0 0 17,000,000 0 0 0 24,051,000           
          cash, cash equivalents and restricted cash, end of period
        		                                11,375,000           
          loss on sales of marketable debt securities
        		                        1,000                   
          loss on impairment of fixed assets
        		                                           
          purchase of viracta common stock
        		                          0                 
          net share settlement for restricted stock unit vesting
        		                                           
          net increase in cash, cash equivalents, and restricted cash
        		                      -75,010,000 85,746,000 1,444,000 -2,783,000 762,000 -5,950,000 6,658,000 1,511,000 -812,000             
          operating lease right-of-use assets
        		                         0 -553,000 0 -247,000               
          sales/maturities of marketable debt securities
        		                       19,811,000 24,609,000 22,630,000 27,829,000 28,882,000 32,918,000 30,080,000 49,633,000 45,711,000 39,860,000           
          net share settlement for restricted stock unit vesting and option exercises
        		                       -40,000 -123,000                   
          proceeds from exercises of stock options and warrants
        		                                           
          gains on sales of marketable debt securities
        		                                           
          deferred rent and revenue
        		                             -138,000 -131,000 -121,000 -118,000 -121,000 -105,000 1,467,000 -40,000       
          principal payments of financing/capital lease obligations
        		                             -142,000 -137,000   -64,000 -14,948,000         
          loss on impairment and loss on disposal of assets
        		                          0                 
          prepaid expenses, other current assets and other assets
        		                          -4,642,000 10,769,000 88,000               
          purchase of debt securities, held-to-maturity
        		                                           
          principal payments of financing lease obligations
        		                                           
          proceeds from exercise of stock options and warrants
        		                          0 0 39,221,000 0 22,000 12,000 23,000  1,000 37,000 1,154,000    660,000   
          net share settlement for rsu vesting, and option and warrant exercises
        		                          -40,000                 
          reconciliation of cash, cash equivalents, and restricted cash at end of period:
        		                                           
          cash and cash equivalents
        		                          1,012,000 -5,000,000 22,279,000 1,511,000 -812,000 4,926,000 11,196,000           
          restricted cash
        		                          -250,000 -950,000 1,379,000               
          supplemental disclosure of cash flow information:
        		                                           
          cash paid during the period for:
        		                                           
          interest
        		                          5,000 0 3,000 258,000 38,000 145,000 34,000 36,000 394,000 201,000 37,000 37,000      
          income taxes
        		                          0   0 0   0 0   1,000 0 0 1,000 -5,000 5,000 
          supplemental disclosure of non-cash investing and financing activities:
        		                                           
          property and equipment purchases included in accounts payable, accrued expenses, and other liabilities
        		                          -1,120,000 -723,000 2,031,000 227,000 -2,267,000             
          conversion of viracta convertible notes and accrued interest into investment in equity securities of viracta
        		                          0 0 751,000               
          unrealized gains on marketable debt securities
        		                          31,000 122,000 118,000 90,000              
          cashless exercise of stock options and warrants
        		                          0       0    0 0     
          amortization of net premiums on marketable debt securities
        		                           -40,000 41,000 81,000 39,000 142,000 201,000           
          operating lease liability, less current portion
        		                           -754,000 -655,000               
          amortization of operating lease right-of-use assets
        		                            624,000               
          net share settlement for rsu vesting and option exercises
        		                            -26,000  0 -80,000 -43,000 -330,000 0 -159,000 -550,000       
          cashless exercise of stock options
        		                            29,000               
          gain on sales of marketable debt securities
        		                                           
          purchase of investment in equity securities
        		                                           
          repurchase of common stock with commissions
        		                                  0         
          restricted cash included in other assets
        		                             0 0 0 179,000           
          property and equipment purchases acquired under capital lease
        		                                 0 0         
          estimated fair value of building under build-to-suit lease
        		                                           
          lease incentive with a related party
        		                                           
          purchase of equity investment
        		                                           
          cashless exercise of warrants
        		                              93,000           -230,000 807,000 
          cash, cash equivalents, and restricted cash at end of period
        		                                           
          property and equipment purchases acquired under capital lease expenses
        		                                           
          unrealized gain on marketable debt securities
        		                               107,000 -174,000           
          purchases of marketable debt securities
        		                                -32,038,000           
          net increase in cash, cash equivalents and restricted cash
        		                                -12,676,000           
          reconciliation of cash, cash equivalents and restricted cash at end of period:
        		                                           
          cash, cash equivalents and restricted cash at end of period
        		                                11,375,000           
          property and equipment purchases included in accounts payable and accrued expenses
        		                                5,930,000  4,159,000 10,910,000 2,492,000  -967,000 985,000 1,074,000   
          amortization of net premiums on marketable securities
        		                                 299,000 358,000 368,000 572,000 615,000 624,000 517,000 426,000   
          gain on sales of marketable securities
        		                                 -7,000 -26,000   -19,000 -49,000 -23,000 -46,000   
          change in value of warrant liability
        		                                           
          loss incurred by inex bio
        		                                         -1,000 0 
          gain on settlement of note payable
        		                                         0 0 
          purchase of cost method investment
        		                                 0 0 0 -8,500,000       
          purchases of marketable securities
        		                                 -36,240,000 -28,597,000 -21,311,000 -25,207,000 -65,108,000 -42,054,000 -54,440,000 -111,397,000   
          sales/maturities of marketable securities
        		                                 67,407,000 46,275,000 86,286,000 54,254,000 58,002,000 51,988,000     
          purchase of inex bio inc., net of cash acquired
        		                                          0 
          proceeds from exercise of stock options
        		                                         35,000 75,000 
          proceeds from exercise of warrants
        		                                         8,000 206,000 
          repayments of notes payable
        		                                           
          net increase in cash and cash equivalents
        		                                 2,952,000 -18,119,000 25,443,000 5,513,000 -23,321,000     238,179,000 
          cash and cash equivalents, beginning of period
        		                                 0 0 0 8,083,000 0 0 0 175,908,000  0 
          cash and cash equivalents, end of period
        		                                 2,952,000 -18,119,000 25,443,000 13,596,000 -23,321,000 -6,819,000 -25,027,000 63,250,000  238,179,000 
          unrealized loss on marketable securities
        		                                           
          estimated fair value of buildings under build-to-suit leases
        		                                     0      
          issuance of warrants in inex bio, inc. acquisition
        		                                          0 
          unrealized gain on marketable securities
        		                                  34,000 4,000 70,000 -608,000 -456,000 166,000 796,000   
          lease incentive
        		                                           
          receivables, net, prepaid expenses and other current assets
        		                                           
          prepaid and other current assets
        		                                    -13,000  -1,025,000 -195,000 -160,000   
          principal payments of financing obligation
        		                                    -22,000       
          amortization of finance issuance costs
        		                                           
          amortization of debt discount
        		                                           
          forgiveness of note receivable from related party
        		                                           
          bad debt expense
        		                                           
          accounts receivable, prepaid and other current assets
        		                                           
          proceeds from exercise of class b common stock
        		                                           
          conversion of debt and payables into common stock
        		                                           
          conversion of debt into series c preferred stock
        		                                           
          change in par value from 0.001 to 0.0001
        		                                           
          conversion of accounts payable against note receivable related party
        		                                           
          property, plant and equipment purchases included in accounts payable and accrued expenses
        		                                           
          deferred revenue
        		                                      -6,000 -4,000 -5,000 -7,000 -6,000 
          purchases of property and equipment
        		                                      -3,079,000 -1,056,000 -1,067,000 -955,000 -1,134,000 
          proceeds from debt and equity offerings, net of issuance costs
        		                                           
          repayments of financing obligations
        		                                           
          employee payroll taxes paid related to net share settlement of restricted stock units
        		                                         0  
          effect of exchange rate changes on cash and cash equivalents
        		                                           
          lease incentives
        		                                           
          investment in intangible assets
        		                                          462,000 
          payments on notes payable
        		                                         0 0 
          net decrease in cash and cash equivalents
        		                                       -25,027,000 -112,658,000   
          sales of marketable securities
        		                                        10,552,000   
          operating activities
        		                                           
          amortization of premiums on marketable securities
        		                                           
          notes receivable from related party
        		                                           
          other current assets
        		                                           
          investing activities
        		                                           
          purchase of inex bio, inc., net of cash acquired
        		                                           
          financing activities
        		                                           
          repurchase of stock
        		                                           
          net increase in cash
        		                                           
          cash and cash equivalents, beginning of year
        		                                           
          cash and cash equivalents, end of year
        		                                           
          supplemental disclosure of cash flow information
        		                                           
          issuance of warrants in inex bio acquisition
        		                                           
          notes received for purchase of class b common stock
        		                                           
          estimated fair market value of building under build-to-suit lease
        		                                           
          cash flows used in operating activities:
        		                                           
          change in fair value of warrant derivative liability
        		                                          0 
          change in value of note payable
        		                                           
          changes in operating assets and liabilities, net of effects of acquisition:
        		                                           
          accrued expenses
        		                                          -1,492,000 
          cash flows used in investing activities:
        		                                           
          cash flows from financing activities:
        		                                           
          conversion of debt into preferred series c stock
        		                                           
          finance issuance costs